

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 06/29/2005

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/055,744	04/07/1998	CHARLES D. Y. SIA	1038-746-MIS	4350
7590 06/29/2005		EXAMINER		
MICHAEL I STEWART			LE, EMILY M	
SIM AND MCBURNEY 330 UNIVERSITY AVENUE 6TH FLOOR			ART UNIT	PAPER NUMBER
TORONTO, M5G1R7			1648	
CANADA				

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.		Applicant(s)	
09/055,744		SIA ET AL.	
ĺ	Examiner	Art Unit	
	Emily Le	1648	

Before the Filling of all Appear Brief	Examiner	Art Unit	
	Emily Le	1648	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED 08 June 2005 FAILS TO PLACE THIS APP	PLICATION IN CONDITION FOR A	LOWANCE.	
 The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods: The period for reply expires 5 months from the mailing date 	the same day as filing a Notice of wing replies: (1) an amendment, aff dice of Appeal (with appeal fee) in o ce with 37 CFR 1.114. The reply mu	Appeal. To avoid aba idavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire is Examiner Note: If box 1 is checked, check either box (a) or	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing	g date of the final rejecti	on.
TWO MONTHS OF THE FINAL REJECTION. See MPEP 7. Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	on which the petition under 37 CFR 1.1 tension and the corresponding amount shortened statutory period for reply origing than three months after the mailing da	of the fee. The appropr inally set in the final Offi	iate extension fee ce action; or (2) as
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte a Notice of Appeal has been filed, any reply must be filed AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	
3. The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE belo (c) They are not deemed to place the application in beloappeal; and/or (d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).	nsideration and/or search (see NO ow); tter form for appeal by materially re corresponding number of finally rej	TE below); ducing or simplifying	
 4. The amendments are not in compliance with 37 CFR 1.1 5. Applicant's reply has overcome the following rejection(s) 6. Newly proposed or amended claim(s) would be all 	21. See attached Notice of Non-Co	•	
non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration:		ll be entered and an e	explanation of
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appe	al and/or appellant fa	ils to provide a
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attact	ned.
11. The request for reconsideration has been considered bu See Continuation Sheet.			nce because:
12. Note the attached Information Disclosure Statement(s).		lo(s).	
13. ☑ Other: Newly submitted Figure 1 has been accepted and	<u>d entered</u> .		
		\	

Jeffrey S. Parkin, Ph.D. Primary Examiner, Art Unit 1648 Continuation of 11, does NOT place the application in condition for allowance because:

Applicant's submission has been considered, however, it is not found adequate to the overcome the enablement rejection set forth in the previous office action(s). Applicant contends that the claims are not directed at a method of vaccinating subjects against HIV or treating subjects of HIV infectivity. Applicant argues that the claimed invention is directed at a method of generating HIV-specific cytotoxic T-cell responses in a host.

The Office acknowledges Applicant's contention. However, the issue here is that Applicant has not taught the skilled artisan how to generate HIV specific cytotoxic T cell response to a host to achieve a therapeutic affect without imposing an undue burden of experimentation upon the skilled artisan. In the HIV art, the purpose of generating an HIV specific cytotoxic T cell response is to either to provide therapeutic treatment against HIV infectivity or to provide protection against HIV infectivity, which is further evidenced by Applicant's disclosure. In the instant, Applicant has not shown that either can be achieved without an undue burden on the part of the skilled artisan that practices the claimed invention. Furthermore, Applicant has not provided any guidance to the skilled artisan on how to overcome the challenges that faces HIV vaccination, as detailed in the office action which the Office issued 05/27/2004.